Parkinson’s disease: animal models and dopaminergic cell vulnerability
Tóm tắt
Từ khóa
Tài liệu tham khảo
Akundi, 2011, Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice., PLoS ONE, 6, 10.1371/journal.pone.0016038
Alam, 2004, The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA., Behav. Brain Res., 151, 117, 10.1016/j.bbr.2003.08.014
Andres-Mateos, 2009, Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)., J. Neurosci., 29, 15846, 10.1523/JNEUROSCI.4357-09.2009
Andres-Mateos, 2007, DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase., Proc. Natl. Acad. Sci. U.S.A., 104, 14807, 10.1073/pnas.0703219104
Baiguera, 2012, Late-onset Parkinsonism in NFκB/c-Rel-deficient mice., Brain, 135, 2750, 10.1093/brain/aws193
Baptista, 2013, Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs., PLoS ONE, 8, 10.1371/journal.pone.0080705
BastÃas-Candia, 2013, Combined exposure to agriculture pesticides, paraquat and maneb, induces alterations in the N/OFQ-NOPr and PDYN/KOPr systems in rats: relevance to sporadic Parkinson’s disease., Environ. Toxicol., 10.1002/tox.21943
Berg, 2014, Human adipose-derived mesenchymal stem cells improve motor functions and are neuroprotective in the 6-hydroxydopamine-rat model for parkinson’s disease when cultured in monolayer cultures but suppress hippocampal neurogenesis and hippocampal memory functi., Stem Cell Rev. Rep., 10.1007/s12015-014-9551-y
Berry, 2010, Paraquat and Parkinson’s disease., Cell Death Differ., 17, 1115, 10.1038/cdd.2009.217
Betarbet, 2000, Chronic systemic pesticide exposure reproduces features of Parkinson’s disease., Nat. Neurosci., 3, 1301, 10.1038/81834
Bezard, 1997, A chronic MPTP model reproducing the slow evolution of Parkinson’s disease: evolution of motor symptoms in the monkey., Brain Res., 766, 107, 10.1016/S0006-8993(97)00531-3
Blandini, 2008, The 6-hydroxydopamine model: news from the past., Parkinsonism Relat. Disord., S124, 10.1016/j.parkreldis.2008.04.015
Blesa, 2010, Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study., Neurobiol. Dis., 38, 456, 10.1016/j.nbd.2010.03.006
Blesa, 2011, Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson’s disease., Front. Syst. Neurosci., 5, 10.3389/fnsys.2011.00092
Blesa, 2012, The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study., Neurobiol. Dis., 48, 79, 10.1016/j.nbd.2012.05.018
Brehm, 2014, A genetic mouse model of Parkinson’s disease shows involuntary movements and increased postsynaptic sensitivity to apomorphine., Mol. Neurobiol., 10.1007/s12035-014-8911–8916
Brichta, 2013, Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems., Trends Neurosci., 36, 543, 10.1016/j.tins.2013.06.003
Brooks, 1999, Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss., Brain Res., 823, 1, 10.1016/S0006-8993(98)01192-5
Cadet, 2007, Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms., Neurotox. Res., 11, 183, 10.1007/BF03033567
Campos, 2013, Rodent models of Parkinson’s disease: beyond the motor symptomatology., Front. Behav. Neurosci., 7, 10.3389/fnbeh.2013.00175
Cannon, 2009, A highly reproducible rotenone model of Parkinson’s disease., Neurobiol. Dis., 34, 279, 10.1016/j.nbd.2009.01.016
Capela, 2009, Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview., Mol. Neurobiol., 39, 210, 10.1007/s12035-009-8064–8061
Chege, 2014, Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson’s disease., Front. Aging Neurosci., 6, 10.3389/fnagi.2014.00089
Chen, 2012, (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD., Cell Death Differ., 19, 1623, 10.1038/cdd.2012.42
Chen, 2006, Proteasome dysfunction in aged human alpha-synuclein transgenic mice., Neurobiol. Dis., 23, 120, 10.1016/j.nbd.2006.02.004
Chiueh, 1984, Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey., Psychopharmacol. Bull., 20, 548
Costa, 2013, MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice., Mov. Disord., 28, 1957, 10.1002/mds.25646
Dantuma, 2014, The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution., Front. Mol. Neurosci., 7, 10.3389/fnmol.2014.00070
Dauer, 2002, Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP., Proc. Natl. Acad. Sci. U.S.A., 99, 14524, 10.1073/pnas.172514599
Dauer, 2003, Parkinson’s disease: mechanisms and models., Neuron, 39, 889, 10.1016/S0896-6273(03)00568-3
Dawson, 2010, Genetic animal models of Parkinson’s disease., Neuron, 66, 646, 10.1016/j.neuron.2010.04.034
Day, 1999, A mechanism of paraquat toxicity involving nitric oxide synthase., Proc. Natl. Acad. Sci. U.S.A., 96, 12760, 10.1073/pnas.96.22.12760
Decressac, 2012, Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons., Neurobiol. Dis., 45, 939, 10.1016/j.nbd.2011.12.013
Dong, 2002, Overexpression of Parkinson’s disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP., J. Neurobiol., 53, 1, 10.1002/neu.10094
Drui, 2014, Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease., Mol. Psychiatry, 19, 358, 10.1038/mp.2013.3
Dunnett, 2010, Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson’s disease., Prog. Brain Res., 184, 35, 10.1016/S0079-6123(10)840038
Dusonchet, 2011, A rat model of progressive nigral neurodegeneration induced by the Parkinson’s disease-associated G2019S mutation in LRRK2., J. Neurosci., 31, 907, 10.1523/JNEUROSCI.5092-10.2011
Ekstrand, 2007, Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons., Proc. Natl. Acad. Sci. U.S.A., 104, 1325, 10.1073/pnas.0605208103
El Ayadi, 2011, Low concentrations of methamphetamine can protect dopaminergic cells against a larger oxidative stress injury: mechanistic study., PLoS ONE, 6, 10.1371/journal.pone.0024722
Exner, 2012, Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences., EMBO J., 31, 3038, 10.1038/emboj.2012.170
Fleming, 2004, Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone., Exp. Neurol., 187, 418, 10.1016/j.expneurol.2004.01.023
Forno, 1986, Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys., Ann. Neurol., 20, 449, 10.1002/ana.410200403
Freire, 2012, Pesticide exposure and Parkinson’s disease: epidemiological evidence of association., Neurotoxicology, 33, 947, 10.1016/j.neuro.2012.05.011
Friedman, 2012, Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain., J. Neurosci., 32, 7585, 10.1523/JNEUROSCI.5809-11.2012
Gandhi, 2009, PINK1-associated Parkinson’s disease is caused by neuronal vulnerability to calcium-induced cell death., Mol. Cell, 33, 627, 10.1016/j.molcel.2009.02.013
Gautier, 2008, Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress., Proc. Natl. Acad. Sci. U.S.A., 105, 11364, 10.1073/pnas.0802076105
Giasson, 2002, Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein., Neuron, 34, 521, 10.1016/S0896-6273(02)00682-7
Gispert, 2003, Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation., Mol. Cell. Neurosci., 24, 419, 10.1016/S1044-7431(03)00198-2
Gispert, 2009, Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration., PLoS ONE, 4, 10.1371/journal.pone.0005777
Glajch, 2012, Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson’s disease., Behav. Brain Res., 230, 309, 10.1016/j.bbr.2011.12.007
Goldberg, 2003, Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons., J. Biol. Chem., 278, 43628, 10.1074/jbc.M308947200
Goldberg, 2005, Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1., Neuron, 45, 489, 10.1016/j.neuron.2005.01.041
Gomez-Isla, 2003, Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice., Neurobiol. Aging, 24, 245, 10.1016/S0197-4580(02)00091-X
Gonzalez-Reyes, 2012, Sonic hedgehog maintains cellular and neurochemical homeostasis in the adult nigrostriatal circuit., Neuron, 75, 306, 10.1016/j.neuron.2012.05.018
Good, 2011, Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson’s disease., FASEB J., 25, 1333, 10.1096/fj.10–173625
Granado, 2008a, Early loss of dopaminergic terminals in striosomes after MDMA administration to mice., Synapse, 62, 80, 10.1002/syn.20466
Granado, 2008b, Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice., J. Neurochem., 107, 1102, 10.1111/j.1471-4159.2008.05705.x
Guo, 2012, Drosophila as a model to study mitochondrial dysfunction in Parkinson’s disease., Cold Spring Harb. Perspect. Med., 2, 10.1101/cshperspect.a009944
Halliday, 2009, No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism., Mov. Disord., 24, 1519, 10.1002/mds.22481
Haque, 2012, Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1., J. Biol. Chem., 287, 23162, 10.1074/jbc.M112.346437
Healy, 2008, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study., Lancet. Neurol., 7, 583, 10.1016/S1474-4422(08)70117–70110
Heinzen, 2014, Distinct neurological disorders with ATP1A3 mutations., Lancet. Neurol., 13, 503, 10.1016/S1474-4422(14)70011–70010
Hennis, 2014, Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson’s disease., Neurobiol. Dis., 62, 113, 10.1016/j.nbd.2013.09.009
Hennis, 2013, Behavioral and neurotransmitter abnormalities in mice deficient for Parkin, DJ-1 and superoxide dismutase., PLoS ONE, 8, 10.1371/journal.pone.0084894
Herzig, 2011, LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice., Hum. Mol. Genet., 20, 4209, 10.1093/hmg/ddr348
Hess, 1990, Acute neuropathological changes in the caudate nucleus caused by MPTP and methamphetamine: immunohistochemical studies., J. Neurocytol., 19, 338, 10.1007/BF01188403
Hinkle, 2012, LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors., Mol. Neurodegener., 7, 10.1186/1750-1326-725
Howard, 2011, Methamphetamine neurotoxicity decreases phasic, but not tonic, dopaminergic signaling in the rat striatum., J. Neurochem., 118, 668, 10.1111/j.1471-4159.2011.07342.x
Hwang, 2003, Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice., Brain Res. Mol. Brain Res., 114, 123, 10.1016/S0169-328X(03)00162-1
Ikeda, 2009, Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology., Brain Res., 1250, 232, 10.1016/j.brainres.2008.10.011
Itier, 2003, Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse., Hum. Mol. Genet., 12, 2277, 10.1093/hmg/ddg239
Jackson-Lewis, 2007, Protocol for the MPTP mouse model of Parkinson’s disease., Nat. Protoc., 2, 141, 10.1038/nprot.2006.342
Janezic, 2013, Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model., Proc. Natl. Acad. Sci. U.S.A., 110, E4016, 10.1073/pnas.1309143110
Jankovic, 2005, The role of Nurr1 in the development of dopaminergic neurons and Parkinson’s disease., Prog. Neurobiol., 77, 128, 10.1016/j.pneurobio.2005.09.001
Jensen, 1993, Mapping toxicant-induced nervous system damage with a cupric silver stain: a quantitative analysis of neural degeneration induced by 3,4-methylenedioxymethamphetamine., NIDA Res. Monogr., 136, 133
Jiang, 2005, Age-dependent dopaminergic dysfunction in Nurr1 knockout mice., Exp. Neurol., 191, 154, 10.1016/j.expneurol.2004.08.035
Joselin, 2012, ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons., Hum. Mol. Genet., 21, 4888, 10.1093/hmg/dds325
Kadkhodaei, 2009, Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons., J. Neurosci., 29, 15923, 10.1523/JNEUROSCI.3910-09.2009
Kara, 2014, A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and parkinsonism: phenotype-genotype correlations, 71, 1162, 10.1001/jamaneurol.2014.994
Kim, 2005, Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress., Proc. Natl. Acad. Sci. U.S.A., 102, 5215, 10.1073/pnas.0501282102
Kirik, 2003, Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson’s disease., Proc. Natl. Acad. Sci. U.S.A., 100, 2884, 10.1073/pnas.0536383100
Kirik, 2002, Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system., J. Neurosci., 22, 2780, 10.1523/JNEUROSCI.22-07-02780.2002
Kitada, 2009a, Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice., J. Neurochem., 110, 613, 10.1111/j.1471-4159.2009.06152.x
Kitada, 2009b, Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice., J. Neurochem., 111, 696, 10.1111/j.1471-4159.2009.06350.x
Klein, 2002, Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra., Hum. Gene Ther., 13, 605, 10.1089/10430340252837206
Kogan, 1976, Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels., Eur. J. Pharmacol., 36, 363, 10.1016/0014-2999(76)90090-X
Kowall, 2000, MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons., Neuroreport, 11, 211, 10.1097/00001756-200001170-00041
Lachenmayer, 2012, Genetic animal models for evaluating the role of autophagy in etiopathogenesis of Parkinson disease., Autophagy, 8, 1837, 10.4161/auto.21859
Lam, 2011, Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein., J. Neurosci. Res., 89, 1091, 10.1002/jnr.22611
Langston, 1983, Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis., Science, 219, 979, 10.1126/science.6823561
Lauwers, 2007, Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression., Neurobiol. Aging, 28, 248, 10.1016/j.neurobiolaging.2005.12.005
Lauwers, 2003, Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein., Brain Pathol., 13, 364, 10.1111/j.1750-3639.2003.tb00035.x
Lee, 2010, Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease., Nat. Med., 16, 998, 10.1038/nm.2199
Li, 2009a, The role of transcription factor Pitx3 in dopamine neuron development and Parkinson’s disease., Curr. Top. Med. Chem., 9, 855
Li, 2009b, Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease., Nat. Neurosci., 12, 826, 10.1038/nn.2349
Li, 2010, Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S., J. Neurosci., 30, 1788, 10.1523/JNEUROSCI.5604-09.2010
Lin, 2009, Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein., Neuron, 64, 807, 10.1016/j.neuron.2009.11.006
Lin, 2012, Conditional expression of Parkinson’s disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1., J. Neurosci., 32, 9248, 10.1523/JNEUROSCI.1731-12.2012
Lo Bianco, 2002, alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease., Proc. Natl. Acad. Sci. U.S.A., 99, 10813, 10.1073/pnas.152339799
Lohr, 2014, Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo., Proc. Natl. Acad. Sci. U.S.A., 111, 9977, 10.1073/pnas.1402134111
Lu, 2009, Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein., J. Neurosci., 29, 1962, 10.1523/JNEUROSCI.5351-08.2009
Lücking, 2000, Association between early-onset Parkinson’s disease and mutations in the parkin gene., N. Engl. J. Med., 342, 1560, 10.1056/NEJM200005253422103
Luk, 2012a, Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice., Science, 338, 949, 10.1126/science.1227157
Luk, 2012b, Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice., J. Exp. Med., 209, 975, 10.1084/jem.20112457
Luk, 2014, Modeling Lewy pathology propagation in Parkinson’s disease., Parkinsonism Relat. Disord., S85, 10.1016/S1353-8020(13)70022–70021
Maekawa, 2012, The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities., Mol. Neurodegener., 7, 10.1186/1750-1326-715
Manning-Bog, 2002, The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein., J. Biol. Chem., 277, 1641, 10.1074/jbc.C100560200
Martella, 2009, Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin., Exp. Neurol., 215, 388, 10.1016/j.expneurol.2008.11.001
Masliah, 2000, Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders., Science, 287, 1265, 10.1126/science.287.5456.1265
Masuda-Suzukake, 2014, Pathological alpha-synuclein propagates through neural networks., Acta Neuropathol. Commun., 2, 10.1186/PREACCEPT-1296467154135944
Matsui, 2014, Exploring the pathogenetic mechanisms underlying Parkinson’s disease in medaka fish., J. Parkinsons. Dis., 4, 301, 10.3233/JPD-130289
Matsuoka, 2001, Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter., Neurobiol. Dis., 8, 535, 10.1006/nbdi.2001.0392
McCormack, 2002, Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat., Neurobiol. Dis., 10, 119, 10.1006/nbdi.2002.0507
McDowell, 2012, Animal models of the non-motor features of Parkinson’s disease., Neurobiol. Dis., 46, 597, 10.1016/j.nbd.2011.12.040
Melrose, 2010, Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice., Neurobiol. Dis., 40, 503, 10.1016/j.nbd.2010.07.010
Meredith, 2008, Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol., Park. Relat Disord, 14(Suppl. 2), S112, 10.1016/j.parkreldis.2008.04.012
Miller, 2007, Paraquat: the red herring of Parkinson’s disease research., Toxicol. Sci., 100, 1, 10.1093/toxsci/kfm223
Miller, 2007, Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD., Exp. Neurol., 204, 421, 10.1016/j.expneurol.2006.12.005
Morais, 2014, PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling., Science, 344, 203, 10.1126/science.1249161
Moratalla, 1992, Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine., Proc. Natl. Acad. Sci. U.S.A., 89, 3859, 10.1073/pnas.89.9.3859
Morin, 2014, Modeling dyskinesia in animal models of Parkinson disease., Exp. Neurol., 256, 105, 10.1016/j.expneurol.2013.01.024
Morrow, 2011, Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson’s disease., Neuroscience, 189, 277, 10.1016/j.neuroscience.2011.05.046
Muthane, 1994, Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice., Exp. Neurol., 126, 195, 10.1006/exnr.1994.1058
Ness, 2013, Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis., PLoS ONE, 8, 10.1371/journal.pone.0066164
Nieto, 2006, Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice., Neurobiol. Aging, 27, 848, 10.1016/j.neurobiolaging.2005.04.010
Nordström, 2014, Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson’s disease., Neurobiol. Dis., 10.1016/j.nbd.2014.09.012
Oaks, 2013, Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function., PLoS ONE, 8, 10.1371/journal.pone.0060378
Obeso, 2014, The expanding universe of disorders of the basal ganglia., Lancet, 384, 523, 10.1016/S0140-6736(13)62418–62416
O’Callaghan, 1994, Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse., J. Pharmacol. Exp. Ther., 270, 741
Oliveras-Salvá, 2014, Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice., Neurobiol. Aging, 35, 2625, 10.1016/j.neurobiolaging.2014.04.032
Oliveras-Salvá, 2013, rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration., Mol. Neurodegener., 8, 10.1186/1750-1326-8-44
Ono, 2009, A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice., Parkinsonism Relat. Disord., 15, 649, 10.1016/j.parkreldis.2009.03.002
Ottolini, 2013, The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering., Hum. Mol. Genet., 22, 2152, 10.1093/hmg/ddt068
Palacino, 2004, Mitochondrial dysfunction and oxidative damage in parkin-deficient mice., J. Biol. Chem., 279, 18614, 10.1074/jbc.M401135200
Pan-Montojo, 2010, Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice., PLoS ONE, 5, 10.1371/journal.pone.0008762
Paumier, 2013, Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson’s disease., PLoS ONE, 8, 10.1371/journal.pone.0070274
Perez, 2005, Parkin-deficient mice are not a robust model of parkinsonism., Proc. Natl. Acad. Sci. U.S.A., 102, 2174, 10.1073/pnas.0409598102
Periquet, 2003, Parkin mutations are frequent in patients with isolated early-onset parkinsonism., Brain, 126, 1271, 10.1093/brain/awg136
Pham, 2010, DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments., Genes Brain Behav., 9, 305, 10.1111/j.1601-183X.2009.00559.x
Pifl, 2014, Is Parkinson’s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum., J. Neurosci., 34, 8210, 10.1523/JNEUROSCI.5456-13.2014
Porras, 2012, Modeling Parkinson’s disease in primates: the MPTP model., Cold Spring Harb. Perspect. Med., 2, 10.1101/cshperspect.a009308
Pringsheim, 2014, The prevalence of Parkinson’s disease: a systematic review and meta-analysis., Mov. Disord., 29, 1583, 10.1002/mds.25945
Przedborski, 1995, Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine., Neuroscience, 67, 631, 10.1016/0306-4522(95)00066-R
Purisai, 2005, Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates., Neurobiol. Dis., 20, 898, 10.1016/j.nbd.2005.05.028
Puschmann, 2013, Monogenic Parkinson’s disease and parkinsonism: clinical phenotypes and frequencies of known mutations., Parkinsonism Relat. Disord., 19, 407, 10.1016/j.parkreldis.2013.01.020
Ramonet, 2011, Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2., PLoS ONE, 6, 10.1371/journal.pone.0018568
Rappold, 2011, Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3., Proc. Natl. Acad. Sci. U.S.A., 108, 20766, 10.1073/pnas.1115141108
Rathke-Hartlieb, 2001, Sensitivity to MPTP is not increased in Parkinson’s disease-associated mutant alpha-synuclein transgenic mice., J. Neurochem., 77, 1181, 10.1046/j.1471-4159.2001.00366.x
Recasens, 2014, Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys., Ann. Neurol., 75, 351, 10.1002/ana.24066
Rockenstein, 2002, Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters., J. Neurosci. Res., 68, 568, 10.1002/jnr.10231
RodrÃguez DÃaz, 2001, Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson’s disease., Behav. Brain Res., 122, 79, 10.1016/S0166-4328(01)00168-1
Rodriguez-Oroz, 2009, Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms., Lancet Neurol., 8, 1128, 10.1016/S1474-4422(0970293–70295
Rousseaux, 2012, Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease., Proc. Natl. Acad. Sci. U.S.A., 109, 15918, 10.1073/pnas.1205102109
Rudenko, 2014, Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications., Neurotherapeutics, 4, 738, 10.1007/s13311-014-0284-z
Sacino, 2014, Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice., Proc. Natl. Acad. Sci. U.S.A., 111, 10732, 10.1073/pnas.1321785111
Sanchez, 2014, Unaltered striatal dopamine release levels in young Parkin knockout, Pink1 knockout, DJ-1 knockout and LRRK2 R1441G transgenic mice., PLoS ONE, 9, 10.1371/journal.pone.0094826
Sauer, 1994, Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat., Neuroscience, 59, 401, 10.1016/0306-4522(94)90605-X
Scarffe, 2014, Parkin and PINK1: much more than mitophagy., Trends Neurosci., 37, 315, 10.1016/j.tins.2014.03.004
Schallert, 2000, CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury., Neuropharmacology, 39, 777, 10.1016/S0028-3908(00)00005-8
Schapira, 2014, Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives., Lancet, 384, 545, 10.1016/S0140-6736(14)61010–61012
Schultheis, 2013, Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits., Hum. Mol. Genet., 22, 2067, 10.1093/hmg/ddt057
Seniuk, 1990, Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP., Brain Res., 527, 7, 10.1016/0006-8993(90)91055-L
Sherer, 2003, Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation., Exp. Neurol., 179, 9, 10.1006/exnr.2002.8072
Shimoji, 2005, Absence of inclusion body formation in the MPTP mouse model of Parkinson’s disease., Brain Res. Mol. Brain Res., 134, 103, 10.1016/j.molbrainres.2005.01.012
Singleton, 2003, alpha-Synuclein locus triplication causes Parkinson’s disease., Science, 302, 10.1126/science.1090278
Snow, 2000, Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg., Psychiatry, 68, 313, 10.1136/jnnp.68.3.313
Sonsalla, 1996, Treatment of mice with methamphetamine produces cell loss in the substantia nigra., Brain Res., 738, 172, 10.1016/0006-8993(96)00995-X
Sotiriou, 2010, Selective noradrenergic vulnerability in α-synuclein transgenic mice., Neurobiol. Aging, 31, 2103, 10.1016/j.neurobiolaging.2008.11.010
Su, 2009, Mutant alpha-synuclein overexpression mediates early proinflammatory activity., Neurotox. Res., 16, 238, 10.1007/s12640-009-9053-x
Sziráki, 1994, Methamphetamine protects against MPTP neurotoxicity in C57BL mice., Eur. J. Pharmacol., 251, 311, 10.1016/0014-2999(94)90416-2
Takahashi, 1997, VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity., Proc. Natl. Acad. Sci. U.S.A., 94, 9938, 10.1073/pnas.94.18.9938
Takahashi, 1989, Maneb enhances MPTP neurotoxicity in mice., Res. Commun. Chem. Pathol. Pharmacol., 66, 167
Taylor, 2014, Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus., Neuropharmacology, 76(Pt A), 97, 10.1016/j.neuropharm.2013.08.033
Taylor, 2011, VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson’s disease., Parkinsons Dis., 2011, 10.4061/2011/124165
Taylor, 2010, Behavioral phenotyping of mouse models of Parkinson’s disease., Behav. Brain Res., 211, 1, 10.1016/j.bbr.2010.03.004
Thiruchelvam, 2000, Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson’s disease?, Brain Res., 873, 225, 10.1016/S0006-8993(00)02496-3
Thiruchelvam, 2003, Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson’s disease phenotype., Eur. J. Neurosci., 18, 589, 10.1046/j.1460-9568.2003.02781.x
Thiruchelvam, 2004, Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice., Eur. J. Neurosci., 19, 845, 10.1111/j.0953-816X.2004.03139.x
Thrash, 2009, Methamphetamine-induced neurotoxicity: the road to Parkinson’s disease. Pharmacol. Rep., 61, 966, 10.1016/S1734-1140(09)70158-6
Tieu, 2011, A guide to neurotoxic animal models of Parkinson’s disease., Cold Spring Harb. Perspect. Med., 1, 10.1101/cshperspect.a009316
Tong, 2009, R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice., Proc. Natl. Acad. Sci. U.S.A., 106, 14622, 10.1073/pnas.0906334106
Tong, 2010, Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice., Proc. Natl. Acad. Sci. U.S.A., 107, 9879, 10.1073/pnas.1004676107
Trulson, 1985, Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: tyrosine hydroxylase immunochemistry and quantitative light microscopic studies., Brain Res. Bull., 15, 569, 10.1016/0361-9230(85)90206–90200
Tsika, 2014, Conditional expression of Parkinson’s disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration., Neurobiol. Dis., 71, 345, 10.1016/j.nbd.2014.08.027
Ulusoy, 2010, Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats., Proc. Natl. Acad. Sci. U.S.A., 107, 13159, 10.1073/pnas.1003432107
Ungerstedt, 1968, 6-Hydroxy-dopamine induced degeneration of central monoamine neurons., Eur. J. Pharmacol., 5, 107, 10.1016/0014-2999(68)90164-7
van den Munckhof, 2003, Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons., Development, 130, 2535, 10.1242/dev.00464
van der Putten, 2000, Neuropathology in mice expressing human alpha-synuclein., J. Neurosci., 20, 6021, 10.1523/JNEUROSCI.20-16-06021.2000
Van Rompuy, 2014, Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration., J. Neuropathol. Exp. Neurol., 73, 159, 10.1097/NEN.0000000000000039
Vekrellis, 2011, Pathological roles of α-synuclein in neurological disorders., Lancet Neurol., 10, 1015, 10.1016/S1474-4422(11)70213–70217
Vila, 2000, Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP., J. Neurochem., 74, 721, 10.1046/j.1471-4159.2000.740721.x
Vincow, 2013, The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo., Proc. Natl. Acad. Sci. U.S.A., 110, 6400, 10.1073/pnas.1221132110
Von Coelln, 2004, Loss of locus coeruleus neurons and reduced startle in parkin null mice., Proc. Natl. Acad. Sci. U.S.A., 101, 10744, 10.1073/pnas.0401297101
Wagner, 1979, Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs., Drug Alcohol Depend., 4, 435, 10.1016/0376-8716(79)90076–90070
Wakamatsu, 2008, Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice., Neurobiol. Aging, 29, 574, 10.1016/j.neurobiolaging.2006.11.017
Winner, 2011, Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice., Neurobiol. Dis., 41, 706, 10.1016/j.nbd.2010.12.008
Xiong, 2009, Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson’s disease., PLoS ONE, 4, 10.1371/journal.pone.0007878
Yang, 2014, Mutations in the ATP13A2 gene and parkinsonism: a preliminary review., Biomed Res. Int., 2014, 10.1155/2014/371256
Zhang, 2014, Defective autophagy in Parkinson’s disease: lessons from genetics., Mol. Neurobiol., 10.1007/s12035-014-8787–8785
Zhang, 2012, Age-related changes in dopamine signaling in Nurr1 deficient mice as a model of Parkinson’s disease., Neurobiol. Aging, 33, e7, 10.1016/j.neurobiolaging.2011.03.022
Zhou, 2011, Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake., Int. J. Biol. Sci., 7, 753, 10.7150/ijbs.7.753